Pathogenesis of pregnancy complications in systemic lupus erythematosus

Current Opinion in Rheumatology

Volumn 25, Issue 5, 2013, Pages 591-596

  Ostensen, Monika ^a   Clowse, Megan ^b  

^a St Olav Universtiy Hospital   (Norway)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

intrauterine growth restriction; preeclampsia; pregnancy loss; prematurity; systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; AUTOANTIBODY; BIOLOGICAL MARKER; CARDIOLIPIN ANTIBODY; CHORIONIC GONADOTROPIN; ENDOGLIN; LUPUS ANTICOAGULANT; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ENDOCRINE DISEASE; ENDOTHELIAL DYSFUNCTION; FETUS OUTCOME; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; INTRAUTERINE GROWTH RETARDATION; PATHOGENESIS; PLACENTA CIRCULATION; PLACENTA DEVELOPMENT; PLACENTA INSUFFICIENCY; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; PREMATURITY; PRIORITY JOURNAL; REVIEW; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

FEMALE; FETAL GROWTH RETARDATION; HUMANS; INFANT, NEWBORN; LUPUS ERYTHEMATOSUS, SYSTEMIC; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREMATURE BIRTH;

EID: 84881509730     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328363ebf7     Document Type: Review

References (43)

1. Clowse MEB, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 2008; 199:127e1-127e6.
2. Kwok LW, Tam LS, Zhu TY, et al. Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus. Lupus 2011; 20:829-836.
3. Barnabe C, Faris PD, Quan H. Canadian pregnancy outcomes in rheumatoid arthritis and systemic lupus erythematosus. Int J Rheumatol 2011; 2011:345727.
4. Smyth A, Oliveira GHM, Lahr BD, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010; 5:2060-2068.
5. Cetin I, Mando C, Calabrese S. Maternal predictors of intrauterine growth restriction. Curr Opin Clin Nutr Metab Care 2013; 16:310-319.
6. Trogstad L, Magnus P, Stoltenberg C. Preeclampsia: risk factors and causal models. Best Pract Res Clin Obstet Gynaecol 2011; 25:329-342.
7. Lunghi L, Ferreti ME, Medici S, et al. Control of human trophoblast function. Reprod Biol Endocrinol 2007; 5:6.
8. Raymond D, Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv 2011; 66:497-506.
9. Wallner W, Sengenberger R, Strick R, et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond) 2007; 112:51-57.
10. Sundrani D, Khot V, Pisal H, et al. Gestation dependant changes in angiogenic factors and their associations with fetal growth measures in normotensive pregnancy. PLoS One 2013; 8:e54153.
11. Leslie K, Thilaganathan B, Papageorghiou A. Early prediction and prevention of preeclampsia. Best Pract Res Clin Obstet Gynaecol 2011; 25:343-354.
12. Clowse ME, Chakravarty E, Costenbader KH, et al. Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64:668-674.
13. Vinet E, Labrecque J, Pineau CA, et al. A population-based assessment of live births in women with systemic lupus erythematosus. Ann Rheum Dis 2012; 71:557-559.
14. Shand AW, Algert CS, March L, Roberts CL. Second pregnancy outcomes for women with systemic lupus erythematosus. Ann Rheum Dis 2013; 72:547-551.
15. Sciascia S, Murru V, Sanna G, et al. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost 2012; 10:2512-2518.
16. Carp HJ, Selmi C, Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss. J Autoimmun 2012; 38:J266-J274.
17. Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64:2311-2318.
18. Llanos C, Friedman DM, Saxena A, et al. Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus. Rheumatology (Oxford) 2012; 51:1086-1092.
19. Eliasson H, Wahren-Herlenius M, Sonesson SE, et al. Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation 2011; 124:1919-1926.
20. Izmirly PM, Buyon JP, Saxena A. Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac disease. Curr Opin Rheumatol 2012; 24:466-472.
21. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/ Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126:76-82.
22. Tunks RD, Clowse ME, Miller SG, et al. Maternal auto antibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. Am J Obstet Gynecol 2013; 208:64 e1-64 e7.
23. Nugent JL, Wareing M, Palin V, et al. Chronic glucocorticoid exposure potentiates placental chorionic plate artery constriction: implications for aberrant fetoplacental vascular resistance in fetal growth restriction. Endocrinology 2013; 154:876-887.
24. Ramenghi LA, Martinelli A, De Carli A, et al. Cerebral maturation in IUGR and appropriate for gestational age preterm babies. Reprod Sci 2011; 18:469-475.
25. Hernandez-Andrade E, Stampalija T, Figueras F. Cerebral blood flow studies in the diagnosis and management of intrauterine growth restriction. Curr Opin Obstet Gynecol 2013; 25:138-144.
26. Chernausek SD. Update: consequences of abnormal fetal growth. J Clin Endocrinol Metab 2012; 97:689-695.
27. Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005; 52:514-521.
28. Dong Y, Yu JL. An overview of morbidity, mortality and long-term outcome of late preterm birth. World J Pediatr 2011; 7:199-204.
29. Clowse ME, Wallace DJ, Weisman M, et al. Predictors of preterm birth in patients with mild systemic lupus erythematosus. Ann Rheum Dis 2013. [Epub ahead of print]
30. Voltolini C, Torricelli M, Conti N, et al. Understanding spontaneous preterm birth: from underlying mechanisms to predictive and preventive interventions. Reprod Sci 2013. [Epub ahead of print].
31. Park JS, Park CW, Lockwood CJ, Norwitz ER. Role of cytokines in preterm labor and birth. Minerva Ginecol 2005; 57:349-366.
32. Xiao R, Sorensen TK, Frederick IO, et al. Maternal second-trimester serum ferritin concentrations and subsequent risk of preterm delivery. Paediatr Perinat Epidemiol 2002; 16:297-304.
33. Clowse ME, Magder LS, Petri M. The clinical utility of measuring complement and antidsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. J Rheumatol 2011; 38:1012-1016.
34. Johnson MJ, Petri M, Witter F, Repke JT. Evaluation of preterm delivery in a systemic lupus erythematosus pregnancy clinic. Obstet Gynecol 1995; 86:396-399.
35. Silver RK, MacGregor SN, Sholl JS, et al. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 1993; 169:1411-1417.
36. Namazy JA, Murphy VE, Powell H, et al. Effects of asthma severity, exacerbations and oral corticosteroids on perinatal outcomes. Eur Respir J 2013; 41:1082-1090.
37. Wagner SJ, Craici I, Reed D, et al. Maternal and foetal outcomes in pregnant patients with active lupus nephritis. Lupus 2009; 18:342-347.
38. Ransom CE, Murtha AP. Progesterone for preterm birth prevention. Obstet Gynecol Clin North Am 2012; 39:1-16; vii.
39. Villa PM, Kajantie E, Raikkonen K, et al. Aspirin in the prevention of preeclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG 2013; 120:64-74.
40. Palmsten K, Herná ndez-Diaz S, Kuriya B, et al. Use of disease-modifying antirheumatic drugs during pregnancy and risk of preeclampsia. Arthritis Care Res (Hoboken) 2012; 64:1730-1738.
41. Cobian-Sanchez F, Prefumo F, Bhide A, Thilaganathan B. Second-trimester uterine artery Doppler and spontaneous preterm delivery. Ultrasound Obstet Gynecol 2004; 24:435-439.
42. Roberge S, Giguere Y, Villa P, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012; 31:141-146.
43. Doria A, Cutolo M, Ghirardello A, et al. Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. Arthritis Rheum 2002; 47:202-209.